Steve Schonfeld’s NewAmsterdam Pharma NAMS Stock Holding History

Steve Schonfeld’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.04M	Buy	+89,765	New	+$2.96M	0.01%	856
2025 Q2	–	Sell	-33,457	Closed	-$685K	–	2367
2025 Q1	$685K	Buy	33,457 +13,075	+64%	+$291K	﹤0.01%	1451
2024 Q4	$524K	Buy	+20,382	New	+$433K	﹤0.01%	1371
2024 Q3	–	Sell	-49,433	Closed	-$950K	–	2275
2024 Q2	$950K	Sell	49,433 -72,567	-59%	-$1.46M	0.01%	1231
2024 Q1	$2.89M	Buy	122,000 +55,100	+82%	+$1.12M	0.02%	857
2023 Q4	$747K	Buy	66,900 +2,200	+3%	+$20.2K	0.01%	1140
2023 Q3	$598K	Buy	64,700 +7,400	+13%	+$80.1K	﹤0.01%	1160
2023 Q2	$681K	Buy	57,300 +27,200	+90%	+$361K	0.01%	1109
2023 Q1	$399K	Buy	+30,100	New	+$380K	﹤0.01%	1261

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Steve Schonfeld's NAMS Position: Q2 2026 in Review

Steve Schonfeld opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 89,765 shares worth $3.04M. The stake represents 0.01% of the portfolio and ranks #856 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in NAMS as recently as Q1 2025.

Steve Schonfeld first reported a position in NAMS in Q1 2023 and has held it in 9 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Steve Schonfeld held 89,765 shares of NewAmsterdam Pharma worth $3.04M as of Q2 2026.
NewAmsterdam Pharma was a new Steve Schonfeld position in Q2 2026.
NewAmsterdam Pharma made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #856 holding.
Steve Schonfeld first reported a position in NewAmsterdam Pharma in Q1 2023 and has held it in 9 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.